

Breast cancers



Detect the disease early to limit resistance

Better exploit the immune response and the tumor microenvironment

New therapeutic options to counteract resistance to chemotherapies and targeted therapies



Improve patient - clinician communication



Immune checkpoint inhibitors and the evolution of the T cell repertoire



Evaluation of new sequences and combination therapies



Interaction between cancer-associated fibroblasts and immune infiltrate



Epigenetic plasticity and resistance mechanisms




Combination therapy: immunotherapy, radiotherapy and DNA repair inhibitors




Epithelial-to-mesenchymal transition and iron metabolism

Pediatric cancers


Developing new therapies to combat resistance




Combination therapies with ALK inhibitors in neuroblastoma




Stabilizing the ESWR1-FLI1 oncogene in Ewing sarcoma



Seeking vulnerabilities in the context of STAG2 mutations in Ewing sarcoma



Tyrosine kinase inhibitors in rhabdoid tumors



Proteomics as a novel approach to seek new therapeutic targets

Study non-genetic cell plasticity in the context of resistance



Neuroblastoma






Ewing sarcoma






Retinoblastoma



Study immune microenvironment as a major player in resistance and tumor response



Exploring the tumor microenvironment in neuroblastoma



Immune microenvironment and immunotherapy in rhabdoid tumors



Facilitate oncologist-children-adolescent-young adult-parent communication

Uveal melanoma



Innovative radiotherapy for uveal melanoma: Promuflash

Genetic and epigenetic study of uveal melanoma

Immunotherapy opportunities in uveal melanoma

Human and social science in uveal melanoma



Characterization of genetic heterogeneity



Characterization of genetic alterations



Identification of new therapeutic strategies



Epigenetic circulating biomarkers for disease diagnosis and monitoring

Response and resistance to immune checkpoints



Neo-epitope prediction and SF3B1 mutations



Tumor-infiltrating lymphocytes (TILs)



Neo-epitopes and vaccines

